SUMMARY

Introduction/Objective The aim of this study was to determine the effects of the estrogen and progesterone receptor status on angiogenesis, proliferation, and apoptosis of myoma cells in premenopausal (PreM) and postmenopausal (PostM) women.

Methods This was a cross section; clinical-experimental, retrospective, non-interventional study in the field of the study of fundamental pathogenesis mechanisms of disease using pathohistological materials from the existing archive. The research included 76 patients diagnosed with uterine leiomyomas, operatively treated in the Clinic for Gynecology and Obstetrics, Clinical Centre Kragujevac, Serbia. According to the menstrual status, we formed two experimental subgroups. The first group was PreM women (n = 35; 46.2 ± 5.02 years old), and the second group was PostM women (n = 41; 60.25 ± 5.41 years old). Hematoxylin-eosin staining for myoma and myometrium was conducted, as well as immunohistochemistry for ERα, ERβ, PRα, vascular endothelial growth factor, endoglin, Ki67, and caspase-3.

Results Progesterone receptor was overexpressed in myoma and myometrium of PreM compared to myoma and myometrium of PostM women. Expression of caspase-3 was a statistically significant increase in PostM women compared to PreM group. ERα and ERβ were not changed among groups neither in myoma nor in myometrium samples.

Conclusion According to our data, PRα had higher influence on apoptosis and cell growth than estrogen receptors. Since PRα was increased in PreM in both myoma and myometrium, probably this expression led further to lower expression of apoptotic marker in PreM women.

Keywords: steroid receptors; apoptosis; angiogenesis; premenopausal; postmenopausal

INTRODUCTION

Uterine fibroids, also known as uterine leiomyomas or fibroids are well-limited, pseudo-encapsulated, benign, monoclonal tumors, composed mainly of smooth muscle cells of the uterus uterine leiomyomas, are among the most frequent gynecological tumors in the reproductive period of women. Independently or in association with hyperplasia and adenomyosis, they reach an incidence of 77%, often causing clinically complicated bleeding, which is why they are the leading cause for hysterectomy and a major global health problem [1, 2]. It has been known that uterine leiomyomas are a hormone-dependent disease. However, the mechanism of action is still unknown, and there is increasing evidence that steroid hormones, estrogen and progesterone receptors are not the only modulators of myoma growth [2, 3, 4]. This can be explained with a presence of similar level of circulating hormone in women with and without myoma, with the occurrence of hormone-independent extraterine leiomyoma and the possible absence of their regression in postmenopausal women [5].

Throughout the last decade, high effort has been invested to clarify the role of gonadal steroids, the expression of local growth factors, and factors associated with apoptosis in myoma cells. Recent studies showed local tissue-specific factors (for example, growth factors), as well as somatic mutations in pro and antiapoptotic genomes, participate in the pathogenesis and progression of these tumors, with or without cross-linking with mechanisms of action of steroid hormones. Among the environmental factors, particular attention is drawn to the presence and effect of estrogen and progesterone receptors on the endometrium and myometrial cells in the uterine wall with myoma [3].

The key pathological processes involved in myoma growth are proliferation and hypertrophy of leiomyocytes, apoptosis, angiogenesis, stromal and secondary changes [6]. The most reliable marker of cell proliferation is Ki-67 or a proliferation–cell nuclear antigen, which denotes not only the cells in the divide, but also...
all those in the synthetic phase of the cell cycle [7]. A high level of Ki-67 antigen, detected during the secretory phase, suggests that progesterone has a synergistic effect in the pathogenesis of myoma [8].

Apoptosis is a process of programmed cell death that eliminates dysfunctional and undesirable cells. It is highly regulated by the complex interaction between the pro- and the anti-apoptotic molecules, is performed in one cell independently of the surrounding, and is induced by the activation of caspasases, specific endoproteases that destroy the essential structural components including the genetic material of the cell [9]. Caspase-3 (cas-3), due to its specificity and sensitivity, is a reliable marker of cells that pass the process of programmed cell death. Its activity cannot be detected before apoptosis. It is registered in early stages and detection grows with progression while is reduced only in the final phase of the apoptotic process [10].

Furthermore, angiogenesis is mediated by numerous angiogenic growth factors; the most powerful among them is the vascular endothelial growth factor (VEGF). VEGF affects the degree of microvascular tumor density by stimulating the proliferation of endothelial cells. Variable concentrations of VEGF, depending on the phase of menstrual cycle, are detected in myometrium, stromal and epithelial endometrial elements [11].

During tumor angiogenesis, endothelial cells intensely express endoglin (CD105), while vascular endothelium, stromal and inflammatory cells barely or do not express at all CD105 [12].

Beside the fact that the prevalence of proliferation over apoptosis is a major condition for myoma growth, with this study we tried to indicate that similarities and differences in angiogenesis, proliferative, and apoptotic indexes in myomas and surrounding tissue, are primarily dependent on the expression of steroid hormone receptors. According to previous, the aim of this study was to determine the effects of the ER and PR status on angiogenesis, proliferation, and apoptosis of myoma cells in premenopausal (PreM) and postmenopausal (PostM) women.

METHODS

This was a cross section; clinical-experimental, retrospective, non-interventional study in the field of the study of fundamental pathogenesis mechanisms of disease using pathohistological materials from the existing archive.

The research included 76 patients diagnosed with uterine leiomyomas, operatively treated in the Clinic for Gynecology and Obstetrics, Clinical Centre Kragujevac, Kragujevac, Serbia, in a three-year-long period (2007–2010). According to the menstrual status, two experimental subgroups were formed. The first group was PreM women (n = 35; 46.2 ± 5.02 years old), and the second group was PostM women (n = 41; 60.25 ± 5.41 years old).

Clinical data were collected by insight into disease history and operational protocols of examined patients. We collected information related to gynecological status (menstrual cycle, menarche, menopause, number of deliveries, etc.) and postmenopausal (PostM) women.

The experimental part of the study was carried out on the operative tissue material obtained by hysterectomy. The study was conducted at Department of Pathology, Clinical Centre of Kragujevac, Serbia. The study was done in accord with standards of the institutional Committee on Ethics of the Clinical Center of Kragujevac, Kragujevac, Serbia.

Hematoxylin-eosin staining

Tissue materials were fixed in formalin, embedded in paraffin, and 5-μm sections were stained with hematoxylin-eosin (H&E), and further examined by immunohistochemistry [13]. All pictures are taken in original resolution with ×200 magnification. A representative sample of the myoma without regressive changes is separated for immunohistochemical analysis.

Immunohistochemistry

Paraffin-embedded tissue sections were fixed in 10% neutral buffered formalin and embedded in paraffin using standard pathological protocols. Immunohistochemistry was performed on a single representative block from each case or two (when the surrounding myometrium is not visible along with the myoma on the first block). Antigenic retrieval was processed by submerging the sample in 10 mM citrate buffer (pH 6) or commercial buffer 10 mM EDTA Buffer for Heat-Induced Epitope Retrieval (pH 8), AP-9004-125 (Thermo Scientific, Waltham, MA, USA) and microwaving for 20 minutes at 96°C. Primary monoclonal antibodies were directed against ERα Ab-11 (mouse: 1:500, MS-354-R7, Thermo Scientific), ERβ antibody (mouse/human: 1:200 dilution, MA1-23217, Thermo Scientific), VEGF (rabbit: 1:100 dilution, RB-9031-RQ, Thermo Scientific), Ki-67 (rabbit: 1:100 dilution, RB-9106-R7, Thermo Scientific), PRa Ab-8 (mouse: 1:25 dilution, MS-298-R7, Thermo Scientific), CD105 (rabbit: 1:25 dilution, RB-9291-R7, Thermo Scientific), and cas-3 Ab-3 (human: 1:100 dilution, MS-1123-R7, Thermo Scientific). Tissue sections were incubated with appropriate primary antibody and commercial biotinylated secondary anti-immunoglobulin, at room temperature, according to the manufacturer’s instructions (UltraVision LP Large Volume Detection System: HRP Polymer (Ready-To-Use), TL-125-HL, Thermo Scientific). An evaluation of the immunohistochemical analysis was carried out by a semi-quantitative assessment of the expression of the examined markers, by scaling to the scales specific to each marker. All pictures are taken in original resolution with ×200 magnification.

Expression of estrogens, progesterone, vascular endothelial growth factor, and Ki-67

The expression of ER and PR will be quantified based on the Allred score, i.e. by adding parameters that indicate percentage representation (from 0 to 5) and intensity of cell
expression (from 1 to 3) [14]. The sum of these parameters will represent the values of the total score (from 0 to 8), where the values ≥ 3 was considered positive. The expression of VEGF, Ki-67 and cas-3 was determined based on the percentage of immunoreactive cells. Based on this expression, groups with low (0–15%), moderate (16–30%) and high proliferative or apoptotic index (31–100%) were formed.

**Expression of endoglin**

Immunohistochemical analysis of the expression of endoglin (CD105), an assessment of the degree of angiogenesis will be performed. The right index of intensity of angiogenesis is the density of intra and peritumoral microcirculation or microvessel density. The analysis will be carried out quantitatively by counting blood vessels in zones with their highest density (hot spot areas). We used the recommendations given by Weidner et al. [15] on the magnitude of the field of vision and the counting method. The focal points of the highest density of blood vessels were determined on a small microscopic magnification (×40). Determination of the focus of the largest microvascular density were performed by two researchers independently, with no clinical and pathohistological data available. After that, the counting of individual blood vessels was performed at a mean microscopic magnification (×200), which implies an area of 0.739 mm². The mean value of the results obtained by counting in three visible fields was the result. When counting blood vessels in each “hot zone,” the expression of individual endothelial cells, and not just the lumen of a blood vessel with visible red blood cells, was calculated. After obtaining the data on the number of blood vessels for each case separately, the mean value of the three read fields were calculated. Then the median in relation to which all myomas were classified into two groups, those with low degree and those with a high degree of angiogenesis, accordingly whether the number of blood vessels is less than or equal to or greater than the value of the calculated median.

All immunohistochemical staining were carried out with quality control and specificity of colouring, using positive and negative controls according to the UK National Quality Assessment for Immunocytochemistry. Microscopic tumor analysis and evaluation of marker expression were performed on a microscope of the Carl Zeiss, Axioskop 40 type. Preparations with representative fields were painted using three microscopic enlargements (×40 and ×200) using a Canon PC 1089 camera (Canon Inc., Tokyo, Japan).

**Sampling**

Regarding the method of selecting a study sample from the entire population, all samples of the material archive will be potentially considered for inclusion. The criteria for the involvement of subjects in the study were a pathohistologically verified uterine leiomyomas disease and PreM or PostM status. Excluding criteria for selecting subjects were associated malignant diseases of the ovary and cervix, incomplete clinical data on menstrual status, use of oral contraceptives and other forms of hormonal therapy.

**Statistical analysis**

Statistical processing of results will be performed using a commercial software package SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). In the analysis of the obtained results, descriptive statistics was first used to describe the general characteristics of the sample: absolute numbers and proportions (frequencies, percentages), median and variability measures (standard deviation), maximum and minimum. The regularity of the distribution was evaluated by Kolmogorov–Smirnov test. For the comparison of the mean values of the two variable populations, the independent t-test, Kruskal–Wallis and Mann–Whitney tests were used, and for comparison of the mean variables of populations analysis of variance was used. The dependence of two descriptive variables were carried out using the chi² test and the Fisher test, the dependence of two numerical variables using Pearson’s and Spearman’s correlation coefficient, while the influence of more variables on the binary variable were investigated using a multivariate binary logistic regression.

**RESULTS**

**Hematoxylin staining**

The standard light microscopic analysis is defined histological type of myoma, the mitotic index expressed through the number of mitotic figures on 10 fields of great enlargement, the presence of regressive changes (necrosis, hyaline and myxomatous degeneration, foci of hemorrhage, etc.), the condition of the endometrium and surrounding myometrium (Figure 1A, B).

**Expression of estrogen receptors alpha and beta in myoma and myometrium**

Neither ERα nor ERβ showed statistically significant expression in myoma of PreM compared to PostM women (Figures 2A, B and Figures 2E, F). Similarly, those parameters were not different among examined groups in myometrium samples (Figures 4A, B and Figures 4E, F).

**Expression of progesterone receptor in myoma and myometrium**

PR was over expressed in myoma of PreM compared to myoma of PostM women (Figure 2C and 2G). Also, statistically significant increased values of PRα were detected in myometrium of PreM compared to PostM women (Figure 4C and 4G).

**Expression of the vascular endothelial growth factor in myoma and myometrium**

In myoma tissue, VEGF was not significantly different among groups (Figure 1D and 1H). Similarly, the same result was obtained in myometrium of PreM women compared to PostM women (Figure 4D and 4H).
Figure 1. A: representative image of a human myoma (H&E, magnification: ×200); B: representative image of a human myometrium (H&E, magnification: ×200)

Figure 2. A–D: immunohistochemical expression of ERα, ERβ, PRα, and vascular endothelial growth factor (magnification: ×200) in myoma tissue of premenopausal and postmenopausal women, representative tissue sections; E–H: percentage of expression of ERα, ERβ, PRα, and vascular endothelial growth factor and statistical difference in percentage of myoma cells between premenopausal and postmenopausal women (▲ – median; ■ – minimum; × – maximum)

Figure 3. A–C: immunohistochemical expression of endoglin, Ki67, and Cas-3 (magnification: ×200) in myoma tissue of premenopausal and postmenopausal women, representative tissue sections; D–F: percentage of expression of endoglin, Ki67 and Cas-3, and statistical difference in percentage of myoma cells between premenopausal and postmenopausal women (▲ – median; ■ – minimum; × – maximum)

Figure 4. A–D: immunohistochemical expression of ERα, ERβ, PRα, and vascular endothelial growth factor (magnification: ×200) in myometrium tissue of premenopausal and postmenopausal women, representative tissue sections; E–H: percentage of expression of ERα, ERβ, PRα, and vascular endothelial growth factor and statistical difference in percentage of myometrium cells between premenopausal and postmenopausal women (▲ – median; ■ – minimum; × – maximum)

Figure 5. A: immunohistochemical expression of endoglin, (magnification: ×200) in myometrium tissue of premenopausal and postmenopausal women, representative tissue sections; B: percentage of expression of endoglin and statistical difference in percentage of myometrium cells between premenopausal and postmenopausal women (▲ – median; ■ – minimum; × – maximum)

Figure 6. Correlation between all examined parameters in myoma tissue

DOI: https://doi.org/10.2298/SARH181030023M
Expression of endoglin in myoma and myometrium

In myoma of PreM and PostM women CD105 did not show any difference in its expression (Figure 3A and 3D). However, in myometrium CD105 was statistically significant increase in PreM women compared to PostM women (Figure 5A and 5B).

Expression of Ki67 in myoma

Ki67 was not significantly different among PreM and PostM women (Figure 3B and 3E).

Expression of caspase-3 in myoma

Expression of casp-3 was statistically significant increase in PostM women compared to PreM group (Figure 3C and 3F).

Correlation between all examined parameters in myoma tissue

Expression of cas-3 in myoma tissue of all examined groups was weak, but statistically significant negative correlation with expression of ERβ in the same tissue (Figure 6A). Moreover, expression of cas-3 was in strong and significant negative correlation with PRα in myoma tissue of both PreM and PostM women (Figure 6B).

In strong correlation with expression of PRα was expression of CD105, VEGF and Ki67 as it is showed in Figures (Figures 6C, E, and F). Moreover, expression of Ki67 was in weak but statistically significant correlation with expression of ERβ (Figure 6D) while cas-3 was in negative correlation with ERβ (Figure 6A). Correlations between other examined parameters in tissue of myoma did not show to be significant.

DISCUSSION

Uterine leiomyoma is the most common benign tumor; despite its frequent manifestation the etiology and pathophysiology of this abnormality remain unknown. Extensive knowledge has accumulated on the role of hormones in the growth of leiomyomas because the occurrence of uterine leiomyomas during the fertile period and the regression after menopause indicate that gonadal steroids are central for development of these tumors [7, 16]. In the last decade, special attention was given to the role of estrogens and progestosterone in the pathophysiology of leiomyomas. Uterine leiomyomas have been considered estrogen-dependent tumors, and its role was supported by the finding that continuous gonadotropin-releasing hormone agonist treatment, significantly decreases ovarian estrogen production, is as well associated with reduction in tumor size [17]. In order to achieve their effects, estrogens act trough the activation of estrogen receptors (ERα and ERβ). Both of these receptors exhibit DNA- and ligand-binding domain sequence conservation and they are encoded by two distinct genes, as well as different tissue distribution [17]. In our study, we showed that expressions of those receptors were not different in myoma of PreM compared to PostM women (Figure 1E, F). Nevertheless, expression of ERα and ERβ was not significantly different neither in myometrium of those women (Figure 3E, F). Similarly, Sakaguchi et al. [18] showed that coordinated expression of ERα and ERβ might be necessary for normal estrogen action in myometrium [19]. In addition, it has been shown ERα is phosphorylated at a higher rate on serine in leiomyoma compared with surrounding myometrium, for that reason it is possible that phosphorylated ERα regulated by p44/42 MAPK, will have a role in development of uterine leiomyoma [20, 21].

In recent years, the role of progesterone in uterine leiomyoma pathophysiology has become more established. As in the case of ERs, nuclear PR works as ligand-activated transcription factors and there is two predominant isoforms of PR in humans: PRα and PRβ [17]. In our study, PRα showed to be significantly unregulated in myoma of PreM compared to myoma of PostM women, which showed to be same in myometrium tissue (Figure 1G, 3G). Those finding correlate with the fact that progestosterone is cyclically elevated during the reproductive years, are significantly elevated during pregnancy, and are suppressed after menopause, however it is still very difficult to distinguishing the relative importance of estrogen versus progestosterone [22, 23].

Since it is already a historical fact that leiomyomas are dependent on angiogenesis for their growth and survival, to date it is also found that estrogens and progestins regulate the expression of several potent angiogenic factors, including VEGF and fibroblast growth factor (FGF) [24]. We found that in myoma VEGF was not significantly changed regardless of the menopausal status (Figure 2H); in contrast, VEGF was changed between groups in myometrium (Figure 4H). We found that VEGF is significantly increased in PreM compared to the PostM women. Similarly, Hague et al. [25], according to menopausal status found that VEGF was significantly increased in PreM compared with PostM endometrium. With the PreM tissue, exhibiting a significantly higher level of expression was found in the epithelium but not in the stroma or the blood vessels [26].

Furthermore, one of the most commonly assessed angiogenesis markers is microvessel density, which is determined on the bases of specific endothelial antigen expression (CD34, CD105) [27]. In the tumor we did not notice any change between groups in expression of CD105 regarding menopausal status (Figure 3D), however CD105 was statistically significantly decreased in myometrium of PostM compared to PreM women (Figure 5B).

Moreover, regarding cell death, we evaluated two proteins known as markers involved in growth control of leiomyoma. There was no difference between two examined groups in expression of Ki67 (Figure 3E); however, cas-3 was significantly increased in PostM compared to PreM women (Figure 3F). We noticed that expression of Ki67 did not follow the trend of cas-3 expression, regarding that Plewka et al. [7] showed that the apoptosis was not accompanied by proliferation. There were no immunolocalization of Ki-67 detected in leiomyomas manifesting apoptosis [28].
Additionally, as we can see from Figure 6, PRa is in positive correlation with VEGF, CD105 and Ki67 (Figure 6C, E and F) in myoma cells, and in negative correlation with cas-3 (Figure 6B). On the other hand, ERβ was in negative correlation with cas-3 and in positive correlation with Ki67 (Figure 6A, D).

**CONCLUSION**

Although ERβ have effect on cell proliferation and apoptosis, according to all the data, PRa seems to be more relevant. According to our data, PRa had higher influence on apoptosis and cell growth then ER. Since PRa was increased in PreM in both myoma and myometrium, this expression probably led further to lower expression of the apoptotic marker, increased cell proliferation, and angiogenesis in PreM women.

Further studies need to be conducted in order to better understand the mechanisms associated with progesterone-driven growth, according to our data, in order to develop therapies that are more efficient.

**Conflict of interest:** None declared.

**REFERENCES**

1. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124(10):1501–12.
2. Patel B, Biguero S, Thakore S, Dahoud W, Bedaivy M, Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology, Hum Reprod Update. 2015; 21(2):155–73.
3. Yun BS, Seong SJ, Cha DH, Kim JY, Kim ML, Shim JY, et al. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Eur J Obstet Gynecol Reprod Biol. 2015; 191:62–7.
4. Spär C. Uterine myomas in pregnancy, childbirth and puerperium. Srp Arh Celok Lek. 2014; 142(1–2):118–24.
5. Sen N, Demirkan NC, Colakoglu N, Duzcan SE. Are there any differences in the expression of hormonal receptors and proliferation markers between uterine and extraterine leiomyomas? Acta J Surg Pathol. 2008; 16(1):43–7.
6. Maruo T, Ohara N, Wang J, Matuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004; 10(3):207–20.
7. Plewka A, Plewka D, Madiej P, Nowaczczyk G, Sieron-Stoltny K, Jakublicz-Barntik B. Processes of apoptosis and cell proliferation in uterine myomas originating from reproductive and perimenopausal women. Folia Histochem Cytobiol. 2011; 49(3):398–404.
8. Borahay MA, Al-Hendy A, Kilic GS, Boehning D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol Med. 2015; 21:242–56.
9. Commandeur AE, Styer AK, Teixeira JM. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 2015; 21(3):593–615.
10. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013; 19(4):406–18.
11. Konarska M, Wrona AN, Aleksandrovych V, Bereza T, Sawiecz M, Gach-Kuniewicz B, et al. Angiogenesis and pro-angiogenic factors in uterine fibroids – facts and myths. Folia Med Cracov. 2016; 56(2):37–43.
12. Saarelainen SK, Staff S, Petlonen N, Lehtimäki T, Isola J, Kujala PM, et al. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma. Tumour Biol. 2014; 35(5):4651–7.
13. Heidenhain M. Noch einmal über die darstellung der centraliskoppe durch inseaminotxolyn. Wiss Mikrosk. 1896; 13:186.
14. Suvarna KS, Layton CH, Bancroft JD, Editors. Bancroft's Theory and Practice of Histological Techniques. 8th edition. Churchill Livingstone/Elsevier Science, 2018.
15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Eng J Med. 1991; 324(1):1–8.
16. Wu X, Blanck A, Olovsson M, Möller B, Favinis R, Lindblom B. Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. Acta Obstet Gynecol Scand. 2000; 79(5):397–404.
17. Borahay MA, Al-Hendy A, Kilic GS, Boehning D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol Med. 2015; 21:242–56.
18. Sakaguchi H, Fujimoto J, Aoki I, Yamaya T. Expression of estrogen receptor alpha and beta in myometrium of premenopausal and postmenopausal women. Steroids. 2003; 68(1):11–9.
19. Plewka D, Marczyński J, Morek M, Boguña E, Plewka A. Receptors of hypothalamic-pituitary-ovarian-axis hormone in uterine myomas. Biomed Res Int. 2014; 2014:521313.
20. Avowole IO, Makinde ON, Badejoko OO, Omoniyi-Esan GO, Tijani O, Ajenifuja KO, et al. Clinical correlates of leiomyoma estrogen and progesterone receptors among Nigerian women. Int J Gynaecol Obstet. 2016; 133(3):314–8.
21. Levy G, Hill MJ, Plowden TC, Catherino WH, Armstrong AY. Biomarkers in uterine leiomyoma. Fertil Steril. 2013; 99(4):1146–52.
22. Tsigkou A, Reis FM, Lee MH, Jiang B, Tosti C, Cantini G, et al. Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms. Fertil Steril. 2015; 104(1):70–5.e1.
23. Lagana AS, Vergara D, Favilli A, La Rosa VL, Tinelli A, Gerli S, et al. Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynaecological disease. Arch Gynecol Obstet. 2017; 296(5):855–67.
24. Konarska M, Wrona AN, Aleksandrovych V, Bereza T, Sawiecz M, Gach-Kuniewicz B, et al. Angiogenesis and pro-angiogenic factors in uterine fibroids – facts and myths. Folia Med Cracov. 2016; 56(2):37–43.
25. Hague S, Manek S, Oehler MK, Mackenzie IZ, Bicknell R, Rees MC. Tamoxifen induction of angiogenic factor expression in endometrium. Br J Cancer. 2002; 86(5):761–7.
26. Jawad M, Ziamajidi N, Foroughi S, Abbasalipourkabir R. Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-α (ER-α) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female Sprague-Dawley rats. Int J Biol Macromol. 2017; 96:706–12.
27. Tal R, Segars JH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update. 2014; 20(2):194–216.
28. Tinelli A, Spär C, Kadlja S, Babovic I, Tinelli R, Mlynářová OA, et al. Myomas: anatomy and related issues. Minerva Ginecol. 2016; 68(3):261–73.
Утицај експресије стероидних рецептора на антигеноезу, пролиферацију и апоптозу у миомима пременопаузних и постменопаузних жене

Душко Кљакић1, Саша Рачевић2, Милош Милосављевић3, Милена Илић4, Александар Живановић5, Драган Радоњић6, Слободанка Митровић7

1Општа болница Бар, Бар, Црна Гора;
2Клинички центар Црна Гора, Клиника за гинекологију и акушерство, Подгорица, Црна Гора;
3Универзитет у Крагујевцу, Факултет медицинских наука, Катедра за патологију, Крагујевца, Србија;
4Универзитет у Крагујевцу, Факултет медицинских наука, Катедра за гинекологију и акушерство, Крагујевца, Србија;
5Институт за трансфузију крви, организациона јединица Бар, Бар, Црна Гора

САЖЕТАК
Увод/Циљ Циљ ове студије је био да се утврди утицај експресије стероидних рецептора на маркере антигеноезе, пролиферације и апоптозе ћелија миома код жена у пременопаузи и постменопаузи.

Методе Ово је била студија пресека, клиничко-експериментална, ретроспективна, неинтервенцијска студија у пољу истраживања фундаменталних механизама патогенезе болести, коришћењем патохистолошких материјала из постојеће архиве. Истраживањем је обухватао 76 болесника са дијагностикованим лејомиоима утеруса, оперативно лечених на Клиници за гинекологију и акушерство Клиничког центра Крагујевца, Србија. Према менструалном статусу, формиране су две експерименталне подгрупе. Прва група биле су жене у пременопаузи (n = 35; 46,2 ± 5,02 година), а друга група биле су жене у постменопаузи (n = 41; 60,25 ± 5,41 година). Коришћено је бојење H&E за миом и миометријум, као и имунохистохемија за ERα, ERβ, PRα, васкуларни ендотелни фактор раста, эндоглін, Ki67 и caspase 3.

Резултати Прогестеронски рецептор је био више изражен у миому и миометријуму у поређењу са миомом код жена у пременопаузи и постменопаузи. Експресија caspase-3 је статистички значајно повећана у групи жена у постменопаузи у поређењу са групом жена у пременопаузи. ERα и ERβ нису били различити ни у узорцима миома ни миометријума.

Закључак Према нашим подацима, PRα је имао већи утицај на апоптозу и раст ћелија него рецептори за естрогене. Пошто је PRα повећан код жена у пременопаузи у миому и миометријуму, вероватно је ова експресија довела до смањења експресије апоптотског маркера код жена које су у пременопаузи.

Кључне речи: рецептори за стероиде; апоптоза; антигеноеза; пременопауза; постменопауза

The influence of the expression of steroid receptors on angiogenesis, proliferation and apoptosis in myomas of pre- and postmenopausal women